From: A novel genomic signature predicting FDG uptake in diverse metastatic tumors
Training set (n = 71) | Validation set (n = 13) | |
---|---|---|
Age (years) | 58 (28–80) | 58 (36–77) |
Females/males | 40/31 | 9/4 |
LBM | 52.3 (29.5–81.8) | 47.9 (32.8–60.7) |
Baseline blood glucose (mg/dl) | 100.8 (66–149) | 100.1 (78–126) |
Injected dose (mCi) | 11.5 (9.9–13.4) | 11.3 (10,0–12.9) |
PET quantification data | ||
Diameter of the lesion (cm) | 6.4 (1.5–18.9) | 8.1 (2.1–18.3) |
SUVmax | 11.8 (3.7–31.3) | 12.3 (2.7–21.7) |
SUVmed35 | 6.7 (2.4–16.7) | 6.5 (2.0–10.7) |
SULa | 4.8 (1.5–11) | 5.1 (2.3–8.8) |
SUVglu | 6.7 (2–14.9) | 6.5 (2.1–11.5) |
MTV (cm3)a | 45.2 (0.7–434) | 197.4 (2.1–1009) |
TLGa | 358.7 (2.3–3958.1) | 1784 (4.1–9058.1) |
T/B | 9.5 (1.4–35.8) | 10.9 (2.5–26.8) |